Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is a highly prevalent cancer with increasing incidence and a high mortality rate. Recently, a combination of an antiangiogenic drug and an immune checkpoint inhibitor, atezolizumab/bevacizumab, has been adopted as a new standard of care to treat advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Brackenier, Cedric, Kinget, Lisa, Cappuyns, Sarah, Verslype, Chris, Beuselinck, Benoit, Dekervel, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856647/
https://www.ncbi.nlm.nih.gov/pubmed/36672297
http://dx.doi.org/10.3390/cancers15020348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856647/
https://www.ncbi.nlm.nih.gov/pubmed/36672297
http://dx.doi.org/10.3390/cancers15020348

Ejemplares similares